Department of Dermatology, Pediatric Dermatology Service, Sheba Medical Center, Tel-Hashomer, 5262000 Ramat Gan, Israel. E-mail:
Acta Derm Venereol. 2021 Jul 13;101(7):adv00501. doi: 10.2340/00015555-3867.
Targeted medications and immunotherapies are being developed to specifically target the pathways involved in tumours. There is limited experience with these new medications and their cutaneous side-effects in the paediatric population. A retrospective study of all paediatric oncological patients treated with targeted therapies and immunotherapies between 1 January 2013 and 1 August 2020 was carried out in 2 haemato-oncological referral centres. A total of 103 children were included in the study. The median (interquartile range) age was 13 years (8.4-16.9), male:female ratio 1.5:1, median (interquartile range) follow-up was 7 months (2-18). Fifty (48%) of the children developed cutaneous adverse events. Treatment was discontinued in only 3 (6%) cases and was altered in only (2%) 1 case due to a cutaneous adverse event. When targeted therapies and immunotherapies for tumours in children are used, there is an increased incidence of cutaneous adverse events. Nevertheless, treatment modification or discontinuation due to cutaneous side-effects is rarely needed.
靶向药物和免疫疗法正在被开发出来，以专门针对肿瘤相关的途径。在儿科人群中，这些新药物及其皮肤副作用的经验有限。在两个血液肿瘤学转诊中心，对 2013 年 1 月 1 日至 2020 年 8 月 1 日期间接受靶向治疗和免疫治疗的所有儿科肿瘤患者进行了一项回顾性研究。共有 103 名儿童纳入研究。中位（四分位间距）年龄为 13 岁（8.4-16.9），男女比例为 1.5:1，中位（四分位间距）随访时间为 7 个月（2-18）。50 名（48%）儿童出现皮肤不良事件。仅 3 例（6%）因皮肤不良事件而停止治疗，仅 1 例（2%）因皮肤不良事件而改变治疗。当在儿童中使用肿瘤的靶向治疗和免疫疗法时，皮肤不良事件的发生率增加。然而，由于皮肤副作用而进行治疗修改或停止治疗的情况很少见。
